Endeavor

Can Hybrid Immunotherapy Improve Solid Tumor Treatment?

Moffitt researchers test CAR-TIL cells combining tumor navigation and targeted attack

Moffitt Launches Immunotherapy Podcast

Monthly series highlights visionaries in immunotherapy and the breakthroughs that are transforming lives

Moffitt Study Shows New Immune Boost Could Expand Access to Cancer Immunotherapy

Adding a natural protein improves the speed and success of TIL manufacturing, potentially benefiting more patients

Moffitt Experts’ Study Aims to Improve TIL Therapy Process

Tumor-infiltrating lymphocyte therapy is FDA approved to treat melanoma.

TIL Therapy for Advanced Melanoma Offers Promising Results

The study shows 36% of patients experienced a positive response to the therapy

Moffitt Experts Share Discoveries Driving Innovation in Cancer Immunotherapy

The Society for Immunotherapy of Cancer brings together industry leaders to highlight new research and clinical applications in immunotherapy

Moffitt Hosts Inaugural Cell Coast Conference to Spotlight Breakthroughs in Cellular Immunotherapy

Experts discuss the latest advances in CAR T, TIL and TCR therapies

Next Generation of TIL Therapy Being Developed for Head and Neck Cancers

Standard of care fails 80% of patients with advanced squamous cell carcinoma

Moffitt Treats its First Commercial TIL Therapy Patient Since FDA Approval

The one-time T-cell therapy infusion was approved in February